Christopher Eirich studied Health Economics and Business Administration at the University of Bayreuth, the Ludwig-Maximillians University in Munich and the Mahidon in Bangkok.

After his graduation, he worked as a strategy consultant and project manager for IQVIA consulting services (the former IMS Consulting Group) on projects in the area of pricing & market access, brand and commercial strategy as well as commercial due diligence (buy side/ sell side).

Since joining Hexal/ Sandoz, he works as Manager for Business and Customer Insights in the area of specialty care (mainly immunology, oncology and hospital business).

The pop-up in your job:

• The most amazing part about my job is, that I have the opportunity to work across many different key brands and TAs within Sandoz with an incredible variety of people, projects and functions – globally and locally. Additionally, I am grateful to work in a highly supportive team of great colleagues.

Hexal is a leader in generic pharmaceuticals and biosimilars in Germany. As a division of the Sandoz Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1,000 molecules, covering all major therapeutic areas, accounted for 2017 sales of USD 10.1 billion. In 2017, our products reached well over 500 million patients. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.